Publication | Open Access

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

Anti-igf-1r Antibody FigitumumabMedicineImmunologyPathologyPreliminary ActivityImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyPhase 1